Copyright Reports & Markets. All rights reserved.

Global Drugs for Dermatophytosis Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Drugs for Dermatophytosis Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Drugs for Dermatophytosis Market Size Growth Rate by Product
      • 1.4.2 Rx
      • 1.4.3 OTC
    • 1.5 Market by End User
      • 1.5.1 Global Drugs for Dermatophytosis Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Drugs for Dermatophytosis Market Size
      • 2.1.1 Global Drugs for Dermatophytosis Revenue 2014-2025
      • 2.1.2 Global Drugs for Dermatophytosis Sales 2014-2025
    • 2.2 Drugs for Dermatophytosis Growth Rate by Regions
      • 2.2.1 Global Drugs for Dermatophytosis Sales by Regions
      • 2.2.2 Global Drugs for Dermatophytosis Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Drugs for Dermatophytosis Sales by Manufacturers
      • 3.1.1 Drugs for Dermatophytosis Sales by Manufacturers
      • 3.1.2 Drugs for Dermatophytosis Sales Market Share by Manufacturers
      • 3.1.3 Global Drugs for Dermatophytosis Market Concentration Ratio (CR5 and HHI)
    • 3.2 Drugs for Dermatophytosis Revenue by Manufacturers
      • 3.2.1 Drugs for Dermatophytosis Revenue by Manufacturers (2014-2019)
      • 3.2.2 Drugs for Dermatophytosis Revenue Share by Manufacturers (2014-2019)
    • 3.3 Drugs for Dermatophytosis Price by Manufacturers
    • 3.4 Drugs for Dermatophytosis Manufacturing Base Distribution, Product Types
      • 3.4.1 Drugs for Dermatophytosis Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Drugs for Dermatophytosis Product Type
      • 3.4.3 Date of International Manufacturers Enter into Drugs for Dermatophytosis Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Drugs for Dermatophytosis Sales by Product
    • 4.2 Global Drugs for Dermatophytosis Revenue by Product
    • 4.3 Drugs for Dermatophytosis Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Drugs for Dermatophytosis Breakdown Data by End User

    6 North America

    • 6.1 North America Drugs for Dermatophytosis by Countries
      • 6.1.1 North America Drugs for Dermatophytosis Sales by Countries
      • 6.1.2 North America Drugs for Dermatophytosis Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Drugs for Dermatophytosis by Product
    • 6.3 North America Drugs for Dermatophytosis by End User

    7 Europe

    • 7.1 Europe Drugs for Dermatophytosis by Countries
      • 7.1.1 Europe Drugs for Dermatophytosis Sales by Countries
      • 7.1.2 Europe Drugs for Dermatophytosis Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Drugs for Dermatophytosis by Product
    • 7.3 Europe Drugs for Dermatophytosis by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Drugs for Dermatophytosis by Countries
      • 8.1.1 Asia Pacific Drugs for Dermatophytosis Sales by Countries
      • 8.1.2 Asia Pacific Drugs for Dermatophytosis Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Drugs for Dermatophytosis by Product
    • 8.3 Asia Pacific Drugs for Dermatophytosis by End User

    9 Central & South America

    • 9.1 Central & South America Drugs for Dermatophytosis by Countries
      • 9.1.1 Central & South America Drugs for Dermatophytosis Sales by Countries
      • 9.1.2 Central & South America Drugs for Dermatophytosis Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Drugs for Dermatophytosis by Product
    • 9.3 Central & South America Drugs for Dermatophytosis by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Drugs for Dermatophytosis by Countries
      • 10.1.1 Middle East and Africa Drugs for Dermatophytosis Sales by Countries
      • 10.1.2 Middle East and Africa Drugs for Dermatophytosis Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Drugs for Dermatophytosis by Product
    • 10.3 Middle East and Africa Drugs for Dermatophytosis by End User

    11 Company Profiles

    • 11.1 Novartis
      • 11.1.1 Novartis Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Novartis Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Novartis Drugs for Dermatophytosis Products Offered
      • 11.1.5 Novartis Recent Development
    • 11.2 Pfizer
      • 11.2.1 Pfizer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Pfizer Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Pfizer Drugs for Dermatophytosis Products Offered
      • 11.2.5 Pfizer Recent Development
    • 11.3 Sanofi-Aventis
      • 11.3.1 Sanofi-Aventis Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Sanofi-Aventis Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Sanofi-Aventis Drugs for Dermatophytosis Products Offered
      • 11.3.5 Sanofi-Aventis Recent Development
    • 11.4 Merck
      • 11.4.1 Merck Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Merck Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Merck Drugs for Dermatophytosis Products Offered
      • 11.4.5 Merck Recent Development
    • 11.5 Enzon Pharmaceuticals
      • 11.5.1 Enzon Pharmaceuticals Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Enzon Pharmaceuticals Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Enzon Pharmaceuticals Drugs for Dermatophytosis Products Offered
      • 11.5.5 Enzon Pharmaceuticals Recent Development
    • 11.6 Bayer
      • 11.6.1 Bayer Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Bayer Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Bayer Drugs for Dermatophytosis Products Offered
      • 11.6.5 Bayer Recent Development
    • 11.7 Astellas Pharma
      • 11.7.1 Astellas Pharma Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Astellas Pharma Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Astellas Pharma Drugs for Dermatophytosis Products Offered
      • 11.7.5 Astellas Pharma Recent Development
    • 11.8 GSK
      • 11.8.1 GSK Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 GSK Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 GSK Drugs for Dermatophytosis Products Offered
      • 11.8.5 GSK Recent Development
    • 11.9 Abbott
      • 11.9.1 Abbott Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Abbott Drugs for Dermatophytosis Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Abbott Drugs for Dermatophytosis Products Offered
      • 11.9.5 Abbott Recent Development

    12 Future Forecast

    • 12.1 Drugs for Dermatophytosis Market Forecast by Regions
      • 12.1.1 Global Drugs for Dermatophytosis Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Drugs for Dermatophytosis Revenue Forecast by Regions 2019-2025
    • 12.2 Drugs for Dermatophytosis Market Forecast by Product
      • 12.2.1 Global Drugs for Dermatophytosis Sales Forecast by Product 2019-2025
      • 12.2.2 Global Drugs for Dermatophytosis Revenue Forecast by Product 2019-2025
    • 12.3 Drugs for Dermatophytosis Market Forecast by End User
    • 12.4 North America Drugs for Dermatophytosis Forecast
    • 12.5 Europe Drugs for Dermatophytosis Forecast
    • 12.6 Asia Pacific Drugs for Dermatophytosis Forecast
    • 12.7 Central & South America Drugs for Dermatophytosis Forecast
    • 12.8 Middle East and Africa Drugs for Dermatophytosis Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Drugs for Dermatophytosis Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Ringworm on the skin like athlete's foot (tinea pedis) and jock itch (tinea cruris) can usually be treated with non-prescription antifungal creams, lotions, or powders applied to the skin for 2 to 4 weeks.
      The global Drugs for Dermatophytosis market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Drugs for Dermatophytosis market based on company, product type, end user and key regions.

      This report studies the global market size of Drugs for Dermatophytosis in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Drugs for Dermatophytosis in these regions.
      This research report categorizes the global Drugs for Dermatophytosis market by top players/brands, region, type and end user. This report also studies the global Drugs for Dermatophytosis market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Novartis
      Pfizer
      Sanofi-Aventis
      Merck
      Enzon Pharmaceuticals
      Bayer
      Astellas Pharma
      GSK
      Abbott

      Market size by Product
      Rx
      OTC
      Market size by End User
      Hospital
      Clinic
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Drugs for Dermatophytosis market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Drugs for Dermatophytosis market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Drugs for Dermatophytosis companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Drugs for Dermatophytosis submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Drugs for Dermatophytosis are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Drugs for Dermatophytosis market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now